Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.

× No keyword cloud information.

4 in total

1. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Authors: Marlon Perera; Nathan Papa; Matthew Roberts; Michael Williams; Cristian Udovicich; Ian Vela; Daniel Christidis; Damien Bolton; Michael S Hofman; Nathan Lawrentschuk; Declan G Murphy
Journal: Eur Urol Date: 2019-02-14 Impact factor: 20.096

2. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review.

Authors: Ricardo Alencar Vilela; Natássia Ferreira Navarro; Edison Tostes Faria; Elaine Barros Ferreira; Rachel Zomer Ruzza; Rafael Gadia; Eliete Neves Silva Guerra; Paula Elaine Diniz Dos Reis
Journal: J Med Imaging Radiat Oncol Date: 2018-05-28 Impact factor: 1.735

3. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Authors: Piet Ost; Barbara Alicja Jereczek-Fossa; Nicholas Van As; Thomas Zilli; Alexander Muacevic; Kenneth Olivier; Daniel Henderson; Franco Casamassima; Roberto Orecchia; Alessia Surgo; Lindsay Brown; Alison Tree; Raymond Miralbell; Gert De Meerleer
Journal: Eur Urol Date: 2015-07-16 Impact factor: 20.096

4. Treatment outcomes of metastasis-directed treatment using ⁶⁸Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002).

Authors: Pervin Hurmuz; Cem Onal; Gokhan Ozyigit; Sefik Igdem; Banu Atalar; Haluk Sayan; Zuleyha Akgun; Meral Kurt; Hale Basak Ozkok; Ugur Selek; Ezgi Oymak; Burak Tilki; Ozan Cem Guler; Teuto Zoto Mustafayev; Irem Saricanbaz; Rashad Rzazade; Fadıl Akyol
Journal: Strahlenther Onkol Date: 2020-07-02 Impact factor: 3.621

4 in total

1 in total

1. Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor.

Authors: L Triggiani; D Tomasini; R Mazzola
Journal: Med Oncol Date: 2021-09-28 Impact factor: 3.064